SCCM Pod-504 CCM: Baricitinib or Tocilizumab for Severe COVID-19
SCCM Podcast
00:00
Comparing Baricitinib and Tocilizumab for Severe COVID-19 Cases
Exploration of the challenges in selecting between Baricitinib and Tocilizumab for severe COVID-19 cases, considering factors like drug availability, cost, and patient outcomes. Discusses the pharmacological profiles, retrospective observational study design, and uncertainties before studying the effects of these drugs on patients with cytokine disturbances. Highlights the discomfort of using immunosuppressive therapies during severe COVID-19 and the importance of future sub-analyses for a better understanding of treatment outcomes.
Transcript
Play full episode
